J&J turns its back on Capri­cor and its failed stem cell tech, tak­ing its mon­ey and rep with it

A lit­tle more than three years ago, J&J stepped up with a $12.5 mil­lion up­front to rent a front row seat on Capri­cor Ther­a­peu­tics’ $CAPR Phase II stem cell study, look­ing to see if their off-the-shelf ap­proach could mend a dam­aged heart. At the time, CEO Lin­da Mar­bán told me that it was well worth the year-long re­view ef­fort need­ed to bring the phar­ma gi­ant to the ta­ble, look­ing to roll ahead with $325 mil­lion in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER